TY  - JOUR
AU  - Leiter, Lawrence A
AU  - Cariou, Bertrand
AU  - Müller-Wieland, Dirk
AU  - Colhoun, Helen M
AU  - Del Prato, Stefano
AU  - Tinahones, Francisco J
AU  - Ray, Kausik K
AU  - Bujas-Bobanovic, Maja
AU  - Domenger, Catherine
AU  - Mandel, Jonas
AU  - Samuel, Rita
AU  - Henry, Robert R
PY  - 2017
DO  - 10.1111/dom.13114
UR  - http://hdl.handle.net/10668/11579
T2  - Diabetes, obesity & metabolism
AB  - To investigate the efficacy and safety of alirocumab in participants with type 2 (T2D) or type 1 diabetes (T1D) treated with insulin who have elevated LDL cholesterol levels despite maximally tolerated statin therapy. Participants at high...
LA  - en
KW  - cardiovascular disease
KW  - clinical trial
KW  - lipid-lowering therapy
KW  - type 1 diabetes
KW  - type 2 diabetes
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Anticholesteremic Agents
KW  - Cardiovascular Diseases
KW  - Diabetes Mellitus, Type 1
KW  - Diabetes Mellitus, Type 2
KW  - Diabetic Angiopathies
KW  - Diabetic Cardiomyopathies
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Drug Resistance
KW  - Female
KW  - Humans
KW  - Hydroxymethylglutaryl-CoA Reductase Inhibitors
KW  - Hypercholesterolemia
KW  - Hypoglycemic Agents
KW  - Injections, Subcutaneous
KW  - Insulin
KW  - Male
KW  - Middle Aged
KW  - Risk
TI  - Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
TY  - research article
VL  - 19
ER  -